Mark Lappe
Chief Executive Officer at Inhibrx Biosciences Inc.
Sits on 1 board. Last updated September 27, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 2 years
- Director since
- 2024
2 years of board service in total across 1 board, counting each seat separately. Longest: Inhibrx Biosciences Inc., 2 years.
Inhibrx Biosciences Inc.
Director · Chief Executive Officer
Chief executive roles
Inhibrx Biosciences Inc.
· Chief Executive Officer
Since May 2024
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Inhibrx Biosciences Inc. | Open-market purchase | +5,895 | $99.29 | $585,343 |
| Sep 8, 2026 | Inhibrx Biosciences Inc. | Open-market purchase | +6,605 | $100.64 | $664,719 |
| Sep 8, 2026 | Inhibrx Biosciences Inc. | Open-market purchase | +1,100 | $107.12 | $117,836 |
| Sep 8, 2026 | Inhibrx Biosciences Inc. | Open-market purchase | +500 | $108.24 | $54,118 |
| Sep 8, 2026 | Inhibrx Biosciences Inc. | Open-market purchase | +1,219 | $111.88 | $136,382 |
| Sep 8, 2026 | Inhibrx Biosciences Inc. | Open-market purchase | +9,681 | $112.28 | $1,087,001 |
| Sep 16, 2024 | Inhibrx Biosciences Inc. | Open-market purchase | +13,037 | $17.13 | $223,324 |
| Sep 12, 2024 | Inhibrx Biosciences Inc. | Open-market purchase | +26,963 | $15.05 | $405,793 |
| Sep 10, 2024 | Inhibrx Biosciences Inc. | Open-market purchase | +8,500 | $15.19 | $129,115 |
| Sep 9, 2024 | Inhibrx Biosciences Inc. | Open-market purchase | +9,500 | $15.21 | $144,495 |
| Sep 6, 2024 | Inhibrx Biosciences Inc. | Open-market purchase | +26,000 | $15.29 | $397,540 |
| Sep 3, 2024 | Inhibrx Biosciences Inc. | Open-market purchase | +15,288 | $15.66 | $239,410 |
| Sep 3, 2024 | Inhibrx Biosciences Inc. | Open-market purchase | +4,712 | $16.31 | $76,853 |
| Aug 30, 2024 | Inhibrx Biosciences Inc. | Open-market purchase | +10,000 | $14.02 | $140,200 |
| Aug 29, 2024 | Inhibrx Biosciences Inc. | Open-market purchase | +10,000 | $14.03 | $140,300 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.